TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Synbiotic Treatment in NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both men and women~* Age \> 18 years~* Liver fat diagnosed on normal clinical grounds including in most cases liver assessed by Kleiner scoring system to classify severity, with no known aetiological factors for underlying liver disease (e.g. exclusion of hepatitis A, B \& C, primary biliary cirrhosis, autoimmune hepatitis, haemochromatosis). Last liver biopsy will be within 3 years of recruitment to the study.~* Liver fat diagnosed by ultrasound, CT or magnetic resonance imaging (MRI) in patients who also have either diabetes and/or features of the metabolic syndrome, without evidence of known aetiological factors for underlying liver disease (e.g. exclusion of hepatitis A, B \& C, primary biliary cirrhosis, autoimmune hepatitis, haemochromatosis).~* Alcohol consumption ≤ 14 units / week for women ≤ 21 units / week for men.~Exclusion Criteria:~* Alcohol consumption \> 15 units /week for women and \> 22 units /week for men.~* Decompensated acute or chronic liver disease.~* A history of viral hepatitis, diarrhoea, diverticulosis, irritable bowel syndrome, inflammatory bowel diseases, coeliac disease (seropositivity for anti-endomysial immunoglobulin A antibodies; immunoglobulin A (IgA) EMA).~* Previous bariatric or other abdominal surgery.~* Continuous use of antibiotics that may change gut microflora, probiotics, or antisecretory drugs capable of causing achlorhydria within the 2 months preceding enrolment, or evidence of immunoglobulin A or immunoglobulin deficiency (both of which produce confounding effects during assessments of intestinal permeability and small intestinal bacterial overgrowth).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Synbiotic (Type: ACTIVE_COMPARATOR): Fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis (BB-12) as minimum of 10 billion colony forming unit (CFU)/day (1 capsule a day).
- Maltodextrin (Type: PLACEBO_COMPARATOR): 4 grams of maltodextrin daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Independent Predictors of Mortality in Polytrauma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* severe trauma (ISS - Injury Severity Score- \>15)~Exclusion Criteria:~* under 18 years old patient,~* technical problems during rescue maneuvers,~* impossibility of blood sample draw during rescue~* informed consent not provided

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- severe trauma patients (Type: None): analysis of blood samples and clinical features

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Analgesic Treatment Versus Traditional Morphine Analgesia After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age\>18~* any cardiac procedure with sternotomy~* able to give informed consent~Exclusion Criteria:~* cardiac surgery without sternotomy~* peripheral neuropathy~* neurological disease~* psychiatric illness~* history of GI bleeding~* chronic pain (i.e. back pain, cancer, arthritis)~* serum creatinine \>150 μmol/l~* hepatic disease with elevated liver enzymes (SGPT and SGOT elevated to 1.5 times maximum normal value)~* allergic to study medication~* alcohol abuse~* abuse of narcotics or medication~* pregnancy~* participation in other clinical trials~* insufficient language skills~* In addition intensive care unit (ICU) stay for more than 24 hours was used as a pre-defined post randomization exclusion criteria, because prolonged ICU stay and ventilator treatment would interfere with study analgesic protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multimodal (Type: EXPERIMENTAL): oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
- Morphine (Type: ACTIVE_COMPARATOR): oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of Rheumatoid Arthritis at least 3 months before screening~* If the patient is of childbearing potential, must have been using adequate birth control measures~* Patients must be receiving MTX for =3 months before randomization and at a stable dose(=25 mg/week) for =4 weeks before randomization~Exclusion Criteria:~* Patients must not be pregnant, nursing, or planning a pregnancy within 18 months of enrollment~* Patients must not have rheumatic disease other than Rheumatoid Arthritis or had any systemic inflammatory condition~* Patients must not be confined to a wheelchair~* Patients must not be treated with any approved or investigational biologic agent except for approved vaccines for immunizations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG Performance Status of ≤ 2 and life expectancy of ≥ 12 weeks.~* Diagnosed with a locally advanced or metastatic malignancy that has progressed despite standard therapy, or for which no effective standard therapy exists. Only patients with tumors characterized by genetic abnormalities in ALK were enrolled.~* For NSCLC, an ALK translocation must be detected by FISH in ≥ 15% of tumor cells.~* In patients with diseases other than NSCLC, ALK translocation is not required and overexpression of ALK protein may be considered indicative of a genetic abnormality in ALK.~* Patients with measurable or non-measurable disease as determined by modified RECIST version 1.0 in dose-escalation phase, and patients with at least one measurable lesion as determined by RECIST 1.0 in expansion phase.~Exclusion Criteria:~* Patients with symptomatic central nervous system (CNS) metastases who were neurologically unstable or required increasing doses of steroids to control their CNS disease were excluded.~* Patients with a prior or current history of a second malignancy, impaired GI function, history of pancreatitis or increased amylase or lipase, known diagnosis of HIV, and clinically significant cardiac disease were excluded.~* Patients treated with chemotherapy or biologic therapy or other investigational agent \< 2 weeks prior to starting study drug for compounds with a half-life ≤ 3 days, and \< 4 weeks prior to starting study drug for compounds with a prolonged half-life were excluded.~* Further, patients treated with medications that were known to be strong inhibitors or inducers of CYP3A4/5 that could not be discontinued at least a week prior to start of treatment with LDK378 and for the duration of the study were also excluded.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDK378 750 mg: Arm 1A and Arm 1B (Type: EXPERIMENTAL): NSCLC patients previously treated with an ALK inhibitor
- LDK378 750 mg: Arm 2 (Type: EXPERIMENTAL): NSCLC patients not previously treated with an ALK inhibitor
- LDK378 750 mg: Arm 3 (Type: EXPERIMENTAL): Patients with other tumors that are ALK positive other than NSCLC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Skin Prep Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing cesarean delivery at Barnes-Jewish Hospital.~Exclusion Criteria:~* Inability to obtain consent; allergy to chlorhexidine, alcohol, iodine, shellfish; and evidence of infection adjacent to operative site.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Iodine-alcohol (Type: ACTIVE_COMPARATOR): 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
- Chlorhexidine-alcohol (Type: EXPERIMENTAL): 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Participants must be ≥18 years of age with a documented history of Generalized Myasthenia Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, and no history of any neurologic disorder other than MG that might interfere with the accuracy of study assessments.~Additional, more specific criteria are defined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None
- Group 4 (Type: EXPERIMENTAL): None
- Group 5 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with T. trichiura by Kato Katz.~* Body weight \>15kg.~* Accepts participation~Exclusion Criteria:~* Albendazole and/or mebendazol treatment in the previous 3 months.~* Allergy to the study drugs~* Acute medical conditions~* Clinical trial participation in the previous 3 months.~* Pregnancy.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole 400mg (Type: ACTIVE_COMPARATOR): Albendazole 400mg in single dose
- Albendazole/Ivermectin (Type: EXPERIMENTAL): Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
- Albendazole 400mg x 3 (Type: EXPERIMENTAL): Albendazole 400mg/day for 3 consecutive days
- Albendazole/Ivermectin x 3 (Type: EXPERIMENTAL): Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients with chronic low platelet count (less than 30,000/µL) for 6 months who have failed at least one treatment for chronic low platelet count.~* Patients receiving chronic maintenance steroid therapy must have received a stable dose for at least 1 month.~* Normal PT and PTT.~Exclusion criteria:~* History of clotting disorder.~* Females who are pregnant or are receiving hormone replacement therapy or systemic contraceptives.~* History of alcohol/drug abuse or dependence within 1 year.~* Use of aspirin, aspirin-containing compounds, salicylates, antacids, rosuvastatin, pravastatin, non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study.~* History of HIV infection or active infection with Hepatitis B or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 2 to \<18 years~* Cough due to upper respiratory tract infection (URI), as determined by physical examination~* Sleep difficulty on the preceding night attributed to frequent cough~* Ability to swallow liquids~* Willingness of the child's guardian to participate in a survey~Exclusion Criteria:~* Signs/symptoms of more serious/treatable disease~* Itchy, watery eyes~* Frequent sneezing, tachypnea (respiratory rate \>95th percentile) or labored breathing; symptoms for 8 or more days.~* History of asthma in the past 2 years~* Chronic lung disease, or seizure disorder~* Allergic reaction to honey or DM~* Selective serotonin reuptake inhibitors (SSRIs) or anti-malarial drugs~* Diabetes mellitus or signs/symptoms of insulin resistance

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1 and 1.2.1 (2004)~* History of migraine of at least 1 year~* Migraine onset before the age of 50 years~* History of 1 - 8 migraine attacks per month~* Male or female subjects aged 18 to 65 years~* Female patients of child-bearing potential must be using a highly effective form of contraception (eg combined oral contraceptive, IUD, abstinence, vasectomized partner)~* Able and willing to return to the clinic for treatment within 4 hours of the onset of a migraine headache~* Able and willing to give written informed consent~Exclusion Criteria:~* History of life threatening or intolerable adverse reaction to any triptan~* Use of prescription migraine prophylactic drugs~* Pregnant or breast-feeding women~* Women of child-bearing potential not using highly effective contraception~* History or evidence of coronary artery disease, ischemic or hemorrhagic stroke, epilepsy or any other condition placing the patient at increased risk of seizures~* History of hypertension (controlled or uncontrolled)~* Sitting BP \>160mmHg systolic or \>90mmHg diastolic on 2 repeated measurements at screening~* Current use of hemodynamically active cardiovascular drugs~* History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol~* Significant renal impairment~* Previous participation in this clinical trial~* Participation in any clinical trial of an experimental drug or device in the previous 30 days~* Any medical condition or laboratory test which in the judgment of the investigator makes the patient unsuitable for the study~* Relatives of, or staff directly reporting to, the investigator~* Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to any excipient of COL-144

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lasmiditan (Type: EXPERIMENTAL): Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received intravenous infusion of placebo solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18.~* Histological diagnosis of adenocarcinoma of rectum.~* Locally advanced/ poor prognosis primary rectal cancer defined by MRI criteria of any of the categories below;~  * Tumour within 2 mm of mesorectal fascia ie circumferential resection margin threatened~ * Any T3 tumour at/below levatores~ * T3c tumour at any other level ie tumour extends \>5 mm into peri-rectal fat~ * T4 tumour~ * Any T stage with 4 or more involved lymph nodes~* WHO performance status 0, 1 or 2.~* No evidence of metastatic disease as determined by CT scan of chest, abdomen, pelvis or other investigations such as PET scan or biopsy if required.~* Adequate bone marrow function with platelets \> 100 X 109/l; WBC \> 3 X 109/l; neutrophils \> 1.5 X 109/l~* Normal renal function, with serum creatinine within the normal range or calculated creatinine clearance \>50 ml/min.~* Adequate hepatic function with serum total bilirubin \< 1.5 X upper limit of normal range.~* No concurrent uncontrolled medical conditions~* No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix~* Adequate contraceptive precautions if relevant~* Informed written consent~Exclusion Criteria:~* Medical or psychiatric conditions that compromise the patient's ability to give informed consent~* Presence of metastatic disease or recurrent rectal tumour~* Renal impairment (creatinine clearance\<30 ml/min)~* Pregnancy or breast feeding~* Patients with a lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes~* Participation in any investigational drug study within the previous 4 weeks.~* Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months)~* Patients with any symptoms or history of peripheral neuropathy.~* Prior pelvic radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Providers:~Inclusion Criteria:~* All primary care providers at the Wade Park Veterans Affairs Medical Center (VAMC) will be eligible for the study~Patients:~Inclusion Criteria:~* Receive primary care from a provider at the Wade Park VAMC~* Have:~  * CKD as defined by an estimated glomerular filtration rate (eGFR) less than 60 on two separate occasions 90 to 730 days apart,~ * diabetes, OR~ * hypertension~Exclusion Criteria:~* End-stage renal disease~* Renal transplant recipients~* Less than 18 years of age on July 1, 2009~* No primary care visit between Jan 1, 2008 and July 1, 2009

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multifactorial intervention (Type: EXPERIMENTAL): The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
- Education only (Type: ACTIVE_COMPARATOR): Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete